Mylan NV

Mylan NV is a multinational pharmaceutical company that develops, licenses, manufactures, markets, and distributes a wide range of generic drugs and over-the-counter medications. Mylan NV operates in over 165 countries and territories, including the United States, Europe, India, Australia, and Japan. The company has a diverse portfolio of products, including EpiPen, Perforomist, and Dymista, which are used to treat various medical conditions, such as allergies, asthma, and chronic obstructive pulmonary disease (COPD) at hospitals like Johns Hopkins Hospital and Massachusetts General Hospital. Mylan NV has partnerships with other pharmaceutical companies, including Pfizer, GSK, and AstraZeneca, to develop and market new products.

● History

Mylan NV was founded in 1961 by Don Panoz and Milan Panić in White Sulphur Springs, West Virginia. The company started as a small pharmaceutical manufacturer and distributor, and over the years, it has grown through mergers and acquisitions, including the acquisition of Matrix Laboratories in 2006 and Merck KGaA's generic drug business in 2007. Mylan NV has also established partnerships with other companies, such as Bayer, Sanofi, and Novartis, to develop and market new products. In 2015, Mylan NV acquired Abbott Laboratories' generic drug business in developed markets, expanding its presence in the United States, Canada, and Europe. The company has also collaborated with research institutions, such as Harvard University and Stanford University, to develop new treatments for various diseases.

● Products

Mylan NV offers a wide range of products, including generic drugs, over-the-counter medications, and biosimilars. The company's product portfolio includes EpiPen, a auto-injector used to treat anaphylaxis, and Perforomist, a bronchodilator used to treat COPD. Mylan NV also markets Dymista, a nasal spray used to treat allergic rhinitis, and Wixela Inhub, a generic version of GlaxoSmithKline's inhaler Advair Diskus. The company has also developed biosimilars for cancer treatments, such as Herceptin and Avastin, in partnership with Biocon and Pfizer. Mylan NV's products are used to treat various medical conditions, including diabetes, hypertension, and infectious diseases, at hospitals like Cleveland Clinic and University of California, Los Angeles.

● Corporate Affairs

Mylan NV is headquartered in Amsterdam, Netherlands, and is led by Heather Bresch, the company's CEO. The company has a global presence, with operations in over 165 countries and territories, including the United States, Europe, India, Australia, and Japan. Mylan NV has a diverse workforce, with employees from various backgrounds, including pharmacists, scientists, and engineers from universities like Massachusetts Institute of Technology and University of Oxford. The company has also established partnerships with patient advocacy groups, such as the Asthma and Allergy Foundation of America and the American Diabetes Association, to raise awareness about various medical conditions and promote access to affordable treatments.

● Financial Performance

Mylan NV is a publicly traded company, listed on the NASDAQ stock exchange under the ticker symbol MYL. The company has reported significant revenue growth over the years, driven by the expansion of its product portfolio and the acquisition of new businesses. In 2020, Mylan NV reported revenues of over $11 billion, with a net income of over $1 billion. The company has also invested heavily in research and development, with a focus on developing new treatments for various diseases, including cancer, HIV, and tuberculosis. Mylan NV has collaborated with financial institutions, such as Goldman Sachs and Morgan Stanley, to raise capital and fund its growth initiatives.

● Controversies

Mylan NV has faced several controversies over the years, including criticism over the pricing of its products, particularly EpiPen. In 2016, the company faced backlash over the significant price increase of EpiPen, which led to a congressional investigation and a settlement with the US Department of Justice. Mylan NV has also faced lawsuits over the marketing of its products, including a lawsuit filed by the State of New York over the company's marketing practices. The company has also been criticized for its tax avoidance strategies, including the use of inversion transactions to reduce its tax liability. Mylan NV has responded to these criticisms by implementing new pricing strategies and increasing transparency around its business practices, in line with US Securities and Exchange Commission regulations and European Union laws.

● Acquisitions and Mergers

Mylan NV has a history of acquisitions and mergers, which has helped the company expand its product portfolio and increase its global presence. In 2015, Mylan NV acquired Abbott Laboratories' generic drug business in developed markets, expanding its presence in the United States, Canada, and Europe. The company has also acquired Meda Pharmaceuticals in 2016, expanding its presence in the European market. In 2019, Mylan NV announced a merger with Upjohn, a division of Pfizer, to create a new company called Viatris. The merger was completed in 2020, and the new company is expected to be a leading player in the global pharmaceutical market, with a presence in over 165 countries and territories, including China, Brazil, and South Africa. Mylan NV has also collaborated with investment firms, such as Kohlberg Kravis Roberts and Blackstone Group, to fund its acquisition and merger activities. Category:Pharmaceutical companies